Get the Stockscreener App
28.50
15.01%
3.72
After Hours:
28.86
0.36
+1.26%
Metsera Inc Stock (MTSR) Latest News
Metsera, Inc. (MTSR): Among Stocks With At Least $10 Million In Insider Spending Recently - Yahoo Finance
CenExel Supports Metsera, Inc. in Successful Phase II Trial of MET-097 for Obesity and Metabolic Diseases - ACCESS Newswire
Metsera to Present at TD Cowen's 45th Annual Health Care Conference - The Manila Times
Metsera to Present at TD Cowen’s 45th Annual Health Care Conference - The Bakersfield Californian
Metsera: Capturing Of Obesity Market With Long-Acting GLP-1 Differentiation - Seeking Alpha
Metsera (NASDAQ:MTSR) Now Covered by Bank of America - Defense World
Metsera (NASDAQ:MTSR) Now Covered by Analysts at Evercore ISI - Defense World
Metsera started by Guggenheim at buy on obesity drug opportunity - MSN
Wall Street bullish on Metsera following January IPO on obesity drug pipeline - Investing.com Canada
Metsera started at buy at Guggenheim on obesity treatment potential - MSN
Why this newly public biotech could become a force in obesity treatments - MarketWatch
90% upside? This weight-loss drug play is worth a look - Invezz
This weight-loss drug stock could deliver a 90% return in 2025 - TradingView
Cantor Fitzgerald initiates Metsera with overweight rating - Investing.com India
Cantor Fitzgerald initiates Metsera with overweight rating By Investing.com - Investing.com Australia
Metsera, Inc.: Buy Rating Affirmed Due to Innovative Obesity Market Approach and Strong Growth Catalysts - TipRanks
Metsera initiated with an Outperform at Evercore ISI - TipRanks
BofA sets Metsera stock Buy rating, $38 price target By Investing.com - Investing.com South Africa
BofA sets Metsera stock Buy rating, $38 price target - Investing.com India
Metsera, Inc.: A Promising Buy in the Obesity Market with Potential for Significant Returns - TipRanks
Guggenheim sets Metsera stock Buy rating, $56 target By Investing.com - Investing.com South Africa
Guggenheim sets Metsera stock Buy rating, $56 target - Investing.com India
Metsera (MTSR): Among Stocks Insiders Spent The Most Money On Recently - Insider Monkey
Metsera hits $2.7 billion valuation as shares surge 42% in Nasdaq debut - MSN
Aardvark Therapeutics Gets $94 Million IPO to Power Obesity Treatments - BioSpace
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters' Option to Purchase Additional Shares - The Manila Times
Metsera Announces Closing of Initial Public Offering and Full Exercise and Closing of Underwriters’ Option to - EIN News
Metsera shares leap on strong IPO performance By Investing.com - Investing.com Nigeria
Metsera shares leap on strong IPO performance - MSN
Metsera IPO opens 42% higher - MSN
Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s - MedCity News
Metsera, Maze land on NASDAQ as IPO queue grows - BioCentury
Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs - MSN
Metsera sees stock rally 54% following $275M IPO - MSN
Finance Watch: Metsera, Maze Go Public, Bringing 2025 US IPO Total To Three - News & Insights
Metsera hits $2.7 bln valuation as shares surge 42% in Nasdaq debut - Reuters
Metsera (MTSR) Opens At $25.50, IPO Priced At $18 By Investing.com - Investing.com Australia
Metsera Inc (MTSR): GLP-1 Boom Comes to the IPO Market with Explosive Debut - Smartkarma
Metsera and Maze Therapeutics Secure $415M in IPOs, Signaling Strong Start for US Health Care Industry - Hoodline
Metsera (MTSR) Opens At $25.50, IPO Priced At $18 - Investing.com
Weight-loss drug developer Metsera raises $275 million in US IPO - MSN
Metsera sees stock rally 54% following $275M IPO (MTSR:NASDAQ) - Seeking Alpha
Metsera IPO opens 42% higher By Investing.com - Investing.com Nigeria
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):